GRACE is celebrating 10 years! In recognition, we would like to introduce you to the staff and board members who are so deeply involved in bringing...
GRACE is celebrating 10 years! In recognition, we would like to introduce you to the staff and board members who are so deeply involved in bringing...
GRACE is celebrating 10 years! In recognition, we would like to introduce you to the staff and board members who are so deeply involved in bringing...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is celebrating 10 years! In recognition, we would like to introduce you to the staff and board members who are so deeply involved in bringing...
Cancer researchers need to hear from lung cancer patients who have gone through chemotherapy and experienced various side effects. As part of that...
Dr. Thomas John is a thoracic oncologist at the Olivia Newton-John Cancer and Wellness Centre in Australia. The American Society of Clinical Oncology...
Last year, an article came out in the Journal of Clinical Oncology that noted a gradual shift away from the "hard endpoint" of overall survival (OS)...
It's been a big week for immunotherapy for lung cancer. Right on the heels of a press release that the PD-1 inhibitor Opdivo (nivolumab) significantly...
In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel)...
1.7 cm solid nodule within the left lateral basilar segment of the left lower lobe with pleural extension, max SUV 1.97 at 60 minutes and 2.23 at 120...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.